Medical Oncology Department, Hospital Universitario Puerta de Hierro Majadahonda, C/Manuel de Falla 1, 28222, Majadahonda, Madrid, Spain.
Med Oncol. 2017 Aug 9;34(9):159. doi: 10.1007/s12032-017-1012-4.
As the overall survival of patients with lung cancer continues to increase, more cancer survivors are faced with the risk of developing treatment-related cardiovascular toxicities. The increased knowledge of the molecular biology of non-small cell lung cancer has led to new and more personalized treatments. Nevertheless, the usual chemotherapy schemes and radiation therapy induce cardiac toxicities that are frequently underappreciated or go unnoticed. Up to date, the majority of cardiotoxicity studies have been focused in breast cancer, but new treatments in lung cancer patients, such as immune checkpoint-blocking antibodies or tyrosine kinase inhibitors, may also exert these cardiac toxic effects and therefore demand of the close collaboration of oncologists and cardiologists, in order to be addressed. The aim of this review is to provide more detailed information in regard to drug-induced cardiac toxicity focused in non-small cell lung cancer patients.
随着肺癌患者的总体生存率持续提高，越来越多的癌症幸存者面临着发生治疗相关心血管毒性的风险。对非小细胞肺癌分子生物学的深入了解，导致了新的、更具个性化的治疗方法。然而，常规的化疗方案和放射治疗会导致经常被低估或忽视的心脏毒性。迄今为止，大多数心脏毒性研究都集中在乳腺癌方面，但肺癌患者的新治疗方法，如免疫检查点阻断抗体或酪氨酸激酶抑制剂，也可能产生这些心脏毒性作用，因此需要肿瘤学家和心脏病学家的密切合作，以解决这些问题。本文旨在提供更详细的关于非小细胞肺癌患者药物相关心脏毒性的信息。
